Bottneuro AG, founded in 2021 as a spin-off from the University of Basel, is a pioneering medtech startup dedicated to transforming the treatment of neurological diseases, with a particular focus on Alzheimer's disease. Headquartered on the Novartis Campus in Basel, Switzerland, Bottneuro has developed the custom-made Miamind® Neurostimulator for fully personalized, non-invasive electrical brain stimulation based on each patient's MRI data. Their innovative approach combines advanced brain imaging with neuromodulation technologies to deliver targeted electrical stimulation to disease-affected brain regions. Bottneuro has completed its first human study and has now initiated treatments with patients in Switzerland.  The recent registration as a custom-made medical device at regulatory bodies including Swissmedic, MHRA, and EUDAMED, enables its clinical prescription for conditions such as Alzheimer's disease, epilepsy and other neurological and psychiatric disorders across Switzerland, the UK, and the EU.